Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 6/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | MC4R | P32245 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | MC3R | P41968 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501507 | 0.79 | KMT2A (0.46) | BAZ2BKMT2ARAB9AKDM4ENPC1 | |
| SCHEMBL4740932 | 0.79 | KMT2A (0.46) | BAZ2BKMT2ARAB9AKDM4ENPC1 | |
| SCHEMBL5139472 | 0.79 | KMT2A (0.54) | KMT2ARAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL11480120 | 0.79 | KMT2A (0.46) | BAZ2BKMT2ARAB9AKDM4ENPC1 | |
| SCHEMBL8862853 | 0.78 | BAZ2B (0.46) | BAZ2BKMT2ARAB9AKDM4ENPC1 | |
| SCHEMBL30518611 | 0.77 | GSK3B (0.44) | BAZ2B | |
| SCHEMBL29078766 | 0.77 | GSK3B (0.44) | BAZ2B | |
| SCHEMBL30373344 | 0.76 | KMT2A (0.51) | KMT2ARAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL20767994 | 0.76 | RAB9A (0.49) | KMT2ARAB9AKDM4ENPC1SMN1; SMN2 | |
| SCHEMBL8862850 | 0.75 | CTH (0.50) | KMT2ARAB9AKDM4ENPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180789-A1 | POLYMERIZATION INITIATOR-CONTAINING COMPOSITION AND DENTAL POLYMERIZABLE COMPOSITION | SUN MEDICAL CO., LTD. (JP) | 2024-06-06 | — | — | US | disclosed |
| WO-2022196757-A1 | POLYMERIZATION INITIATOR-CONTAINING COMPOSITION AND DENTAL POLYMERIZABLE COMPOSITION | サンメディカル株式会社 | 2022-09-22 | — | — | WO | disclosed |
| EP-3388425-B1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2020-08-05 | — | — | EP | disclosed |
| US-10689354-B2 | Aminoazole derivative | TEIJIN PHARMA LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2019-01-31 | — | — | US | disclosed |
| US-10087173-B2 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | BARUCH S. BLUMBERG INSTITUTE | 2018-10-02 | — | — | US | disclosed |
| WO-2017099237-A1 | AMINOAZOLE DERIVATIVE | 帝人ファーマ株式会社 | 2017-06-15 | — | — | WO | disclosed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH | 2017-03-09 | — | — | US | disclosed |
| EP-1622897-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Novartis AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| EP-1608647-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | Novartis AG (CH) | 2005-12-28 | — | — | EP | disclosed |
| WO-2005070926-A1 | THIAZOLE DERIVATIVES AS A2B ANTAGONISTS | NOVARTIS AG (CH) | 2005-08-04 | — | — | WO | disclosed |
| EP-1339711-B1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004096797-A1 | INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004078754-A1 | 5-PHENYLTHIAZOLE DERIVATIVES AND THEIR USE AS P13 KINASE INHIBITORS | NOVARTIS AG (CH) | 2004-09-16 | — | — | WO | disclosed |
| US-20040053982-A1 | Aminothaizoles and their use as adenosine receptor antagonists | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| CN-1476447-A | Aminothiazoles and their use as adenosine receptor antagonists | ��˹��ŵ�� | 2004-02-18 | — | — | CN | disclosed |
| EP-1339711-A1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002042298-A1 | AMINOTHIAZOLES AND THEIR USE AS ADENOSINE RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053982-A1 | Aminothaizoles and their use as adenosine receptor antagonists | ADORA1, ADORA3, HCAR1 | BAZ2B 2209/4885KMT2A 2241/4885RAB9A 2437/4885 |
| US-10689354-B2 | Aminoazole derivative | AR, NR3C2, NR5A1 | BAZ2B 250/4885KMT2A 1490/4885RAB9A 2799/4885 |
| US-20190031628-A1 | AMINOAZOLE DERIVATIVE | AR, NR3C2, NR5A1 | BAZ2B 250/4885KMT2A 1490/4885RAB9A 2799/4885 |
| US-10087173-B2 | Substituted aminothiazoles as inhibitors of cancers, including hepatocellular carcinoma, and as inhibitors of hepatitis virus replication | HDGF, HCCS, BCAT1 | BAZ2B 378/4885KMT2A 281/4885RAB9A 3393/4885 |
| US-20240180789-A1 | POLYMERIZATION INITIATOR-CONTAINING COMPOSITION AND DENTAL POLYMERIZABLE COMPOSITION | TAS2R19, CDK4, CCNT1 | BAZ2B 782/4885KMT2A 1013/4885RAB9A 2034/4885 |
| US-20170066758-A1 | SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION | HDGF, HCCS, BCAT1 | BAZ2B 378/4885KMT2A 281/4885RAB9A 3393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.